While these unanswered questions remain an area of active interest within our group, these data add to a mounting body of clinical and preclinical data suggesting that antiandrogen therapies in combination with radiation may be an effective treatment strategy for women with treatment refractory and radiation-resistant breast cancer, including women with AR-positive triple-negative breast cancer. The gene discussed is AR; the disease is triple-negative breast carcinoma.